Clinical Trials Logo

Skin Squamous Cell Carcinoma clinical trials

View clinical trials related to Skin Squamous Cell Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04234113 Active, not recruiting - Ovarian Cancer Clinical Trials

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Start date: June 13, 2019
Phase: Phase 1
Study type: Interventional

A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors

NCT ID: NCT03944941 Active, not recruiting - Clinical trials for Skin Squamous Cell Carcinoma

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Start date: May 17, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02978625 Active, not recruiting - Clinical trials for Merkel Cell Carcinoma

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Start date: September 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.

NCT ID: NCT02964559 Active, not recruiting - Clinical trials for Skin Squamous Cell Carcinoma

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

Start date: January 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT00954226 Active, not recruiting - Clinical trials for Recurrent Head and Neck Carcinoma

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Start date: August 5, 2009
Phase: Phase 1
Study type: Interventional

This randomized phase Ib trial studies standard-dose or high-dose erlotinib hydrochloride before surgery in treating patients with head and neck cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.